Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L. Hauser, Jerry S. Wolinsky, Kalpesh Prajapati et al.|Neurology|2021Cited by 181
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuß, Amit Bar‐Or, Robert A Bermel et al.|Therapeutic Advances in Neurological Disorders|2024Cited by 23
A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)Giancarlo Comi, Catherine Lubetzki, Robert A Bermel et al.|Neurology|2022Cited by 5
A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)Ralph Benedict, Helmut Butzkeuven, Robert A Bermel et al.|Neurology|2022Cited by 4